AIT Therapeutics (OTCMKTS:AITB) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a research note issued on Wednesday.
According to Zacks, “AIT Therapeutics, Inc. is a clinical-stage anti-microbial therapeutic company using nitric oxide to treat respiratory and other diseases. The Company is currently applying its therapeutic expertise to treat lower respiratory tract infections, which are not effectively addressed with current standards of care. It is advancing its revolutionary respiratory targeted system in clinical trials for the treatment of bronchiolitis and nontuberculous mycobacteria. AIT Therapeutics, Inc. is based in Ness Ziona, Israel. “
Separately, Roth Capital set a $16.00 price target on AIT Therapeutics and gave the stock a “buy” rating in a report on Saturday, December 2nd.
TRADEMARK VIOLATION NOTICE: “AIT Therapeutics (AITB) Stock Rating Lowered by Zacks Investment Research” was posted by Chaffey Breeze and is the property of of Chaffey Breeze. If you are reading this report on another site, it was stolen and republished in violation of international trademark and copyright legislation. The legal version of this report can be read at https://www.chaffeybreeze.com/2018/01/05/ait-therapeutics-aitb-stock-rating-lowered-by-zacks-investment-research.html.
About AIT Therapeutics
AIT Therapeutics, Inc, formerly KokiCare, Inc, is a shell company. The Company is engaged in the discovery and planning phase to develop a real-time, software as a service (SaaS)-based enterprise software application to manage the integration, planning, tracking and management of healthcare assets, which include people, supplies, clinical data, relationships and financial resources of healthcare organizations.
Receive News & Ratings for AIT Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AIT Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.